person

Mayra Lizbeth O.

Country
Spain
Department
Oncology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 10 partner sites.

Specializations

Breast Cancer Therapeutics

The investigator concentrates on advanced and metastatic Breast Cancer, including hormone‑receptor‑positive, HER2‑negative, and triple‑negative subtypes.

  • Hormone‑receptor‑positive HER2‑negative disease
  • Triple‑negative Breast Cancer
  • HER2‑positive metastatic disease
  • Adjuvant strategies for early‑stage disease

Emphasis is placed on integrating targeted agents and immunotherapy within breast oncology.

Hematologic Malignancies

Research activity spans a broad spectrum of Hematologic Malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and various lymphomas.

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Follicular Lymphoma

Focus is on novel agents and cellular therapies for blood cancers.

Lung Cancer & Thoracic Oncology

In thoracic oncology, the investigator addresses both non‑small cell and small‑cell lung cancer subtypes, with attention to molecular drivers.

  • Non‑Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • KRAS‑mutated NSCLC
  • ALK‑positive NSCLC
  • EGFR‑mutated NSCLC

Targeted and immuno‑oncology approaches are central to the lung cancer program.

Gastrointestinal and Hepatobiliary Oncology

The investigator’s portfolio includes malignancies of the gastrointestinal tract and liver, focusing on advanced disease settings.

  • Colorectal Cancer
  • Gastric Cancer
  • Hepatocellular Carcinoma
  • Pancreatic Adenocarcinoma
  • Cholangiocarcinoma

Molecular profiling guides therapeutic selection in these solid tumors.

Rare and Molecularly Targeted Tumors

Additional work targets rare tumors and those defined by specific biomarkers, such as HER2 alterations and KRAS G12C mutations.

  • HER2‑mutated solid tumors
  • KRAS G12C‑positive tumors
  • Uveal Melanoma
  • Neuroendocrine Tumors
  • Mesothelioma

Precision medicine strategies are applied across these uncommon indications.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.